Skip to content
Search

Latest Stories

Decision to leave FIP taken by majority vote, RPS clarifies

After its decision to leave the International Pharmaceutical Federation (FIP) has drawn much criticism, the Royal Pharmaceutical Society (RPS) clarified that the Assembly took the decision by majority vote.

In an open letter, RPS president Prof Claire Anderson conceded that not disclosing the intention to leave FIP membership, though mutually agreed with the global body, was a ‘wrong call’.


Anderson revealed that the RPS Assembly confirmed its intention to FIP in November last year, following discussions regarding RPS membership of a range of international organisations.

“We had concerns regarding the extent of the annual membership fee, the associated costs of participation in FIP events, and attendance at meetings. This amounted to an annual recurring membership fee of around £31,000, and an additional £53,000 in meeting attendance costs, travel and accommodation, etc. in 2019 (the last year a face-to-face FIP Congress was held abroad),” she explained in the letter.

She added that there were two opposing views in the Assembly, with one holding that “there was no perceptible value in membership of FIP as currently experienced, and it was difficult to identify any return on investment” and the other saying that “there would be value if the RPS chose to make better use of its membership.”

“This was a finely balanced decision and one that required a vote; the majority voted to leave FIP membership,” she said.

Anderson added that the RPS has at the same time reconfirmed its position to sponsor the Commonwealth Pharmacy Association, the London-based organisation which has observer status in the FIP.

In her letter, she also defended the need for confidential discussions.

“I would like to stress our preference and first option is always to have discussions and make decisions in public, not in private,” she said. “On occasion, the Assembly, as the key decision-making forum of the RPS, needs to be a place in which Assembly members can freely air differing views and opinions, and debate the full range of policies, strategies, and decisions around use of resources.”

“In my view, these decisions should not be taken via the number of ‘likes’ on a social media post. Indeed, without the opportunity for confidential deliberation, it is hard to see how our system of governance could function,” she added.

Addressing the concerns on the part of members about the future direction of the RPS, she assured that the organisation is committed to putting pharmacy on the forefront of healthcare, and will continue to strive to become the world leader in the safe and effective use of medicines.

“Since the Society was founded in 1841, we have championed the profession and want to do more in education policy and professional development. This has not, and will not, change,” she said.

Anderson also written about the decision relates to changing the name of the organisation to a ‘Royal College’.

“There was a consensus of those present not to pursue Royal College status. It was agreed there was no current impediment to our ambitions in education that our existing Charter and Royal Patronage prohibited, and no material benefit of a change in status to Royal College was identified,” she said.

The decision regarding pursuit of Royal College status was taken in March 2021, when the Assembly was asked to provide a definitive position on whether it should actively pursue the status in the context of developing it five- year strategy, 2021 to 2026.

Anderson also said she is working on mechanism that allow for better two-way dialogue.

“As President I can and will be asking for changes to be made around decision making, how members can be involved and be made better aware of how the RPS decides its policies and direction,” she said.

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less
NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less